The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 20, 2006

Filed:

May. 07, 2002
Applicants:

Theodora Salcedo, Montgomery Village, MD (US);

Steven M. Ruben, Brookeville, MD (US);

Craig A. Rosen, Laytonsville, MD (US);

Vivian R. Albert, Rockville, MD (US);

Claire Dobson, Cambridge, GB;

Tristan Vaughan, Cambridge, GB;

Inventors:

Theodora Salcedo, Montgomery Village, MD (US);

Steven M. Ruben, Brookeville, MD (US);

Craig A. Rosen, Laytonsville, MD (US);

Vivian R. Albert, Rockville, MD (US);

Claire Dobson, Cambridge, GB;

Tristan Vaughan, Cambridge, GB;

Assignee:

Human Genome Sciences, Inc., Rockville, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.


Find Patent Forward Citations

Loading…